<DOC>
	<DOCNO>NCT02428270</DOCNO>
	<brief_summary>This phase 2 study ( second phase test new drug combination see effect drug combination ) investigational drug GSK2256098 Trametinib . The purpose study evaluate antitumor activity GSK2256098 Trametinib patient advance pancreatic cancer .</brief_summary>
	<brief_title>A Study GSK2256098 Trametinib Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Trametinib drug work bind block certain protein call mitogen-activated protein kinase kinase ( MEK ) 1 MEK2 work . MEK1 MEK2 important protein contribute growth cancer cell . GSK2256098 drug block protein call focal adhesion kinase-1 ( FAK ) important protein contribute growth cancer cell .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Male female , 18 year old , able give write consent Pancreatic adenocarcinoma responsive standard therapy approve curative therapy patient refuse standard therapy Have clinical , radiographic , serologic progression one prior line chemotherapy advance disease . Patients receive two prior line chemotherapy advance disease eligible . Performance Status score 0 1 Measureable disease RECIST version 1.1 Able swallow retain oral medication Have malignant disease amenable biopsy agree collection mandatory tumor biopsy sample . Agrees use contraception Not pregnant Adequate organ system function Chemotherapy , radiotherapy , immunotherapy , anticancer therapy include investigational drug within 28 day 5 half life . No prior MEK inhibitor , RAF inhibitor FAK inhibitor Current use prohibit medication Unresolved toxicity great Grade 1 previous anticancer therapy unless ongoing toxicity introduce additional risk factor interfere study procedure . Presence active GI disease condition could affect gastrointestinal absorption predispose GI ulceration Evidence mucosal internal bleeding Anticoagulation warfarin Major surgery within last four week Malignancies relate HIV HBV/HCV Known active infection require parenteral oral antiinfective treatment Leptomeningeal disease . Brain metastases QTcF interval â‰¥ 480 msecs History evidence current clinically significant uncontrolled arrhythmias History acute coronary syndrome , myocardial infarction , coronary angioplasty , stenting bypass graft within six month screen . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Other clinically significant ECG abnormality Intracardiac defibrillator . Presence cardiac metastasis . Serious unstable preexist medical , psychiatric , condition could interfere patient 's safety providing informed consent . Known immediate delay hypersensitivity component study treatment ( ) . Evidence severe uncontrolled systemic disease Pregnant lactate History retinal vein occlusion History interstitial lung disease pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>